UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma

Clinical cancer research, 2009-09, Vol.15 (17), p.5591-5598

2009

Volltextzugriff (PDF)

Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial

The lancet oncology, 2012-09, Vol.13 (9), p.879-886

2012

Volltextzugriff (PDF)

Evaluation of in vivo labelled dendritic cell migration in cancer patients

Journal of translational medicine, 2004-07, Vol.2 (1), p.27-27, Article 27

2004

Volltextzugriff (PDF)

The cost of unresectable stage III or stage IV melanoma in Italy

Journal of experimental & clinical cancer research, 2012-11, Vol.31 (1), p.91-91, Article 91

2012

Volltextzugriff (PDF)

Cisplatin, Dacarbazine With or Without Subcutaneous Interleukin-2, and Interferon Alfa-2b in Advanced Melanoma Outpatients: Results From an Italian Multicenter Phase III Randomized Clinical Trial

Journal of clinical oncology, 2002-03, Vol.20 (6), p.1600-1607

Ridolfi, R.

2002

Volltextzugriff (PDF)

Adding Gemcitabine to Paclitaxel/Carboplatin Combination Increases Survival in Advanced Non–Small-Cell Lung Cancer: Results of a Phase II-III Study

Journal of clinical oncology, 2006-02, Vol.24 (4), p.681-687

2006

Volltextzugriff (PDF)

Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients

Journal of translational medicine, 2006-08, Vol.4 (1), p.36-36, Article 36

2006

Volltextzugriff (PDF)

Unexpected High Response Rate to Traditional Therapy after Dendritic Cell-Based Vaccine in Advanced Melanoma: Update of Clinical Outcome and Subgroup Analysis

Clinical & developmental immunology, 2010-01, Vol.2010 (2010), p.1-9

2010

Volltextzugriff (PDF)

FRET microscopy autologous tumor lysate processing in mature dendritic cell vaccine therapy

Journal of translational medicine, 2010-06, Vol.8 (1), p.52-52, Article 52

2010

Volltextzugriff (PDF)

Biomonitoring of Metals in Children Living in an Urban Area and Close to Waste Incinerators

International journal of environmental research and public health, 2020-03, Vol.17 (6), p.1919

2020

Volltextzugriff (PDF)

Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort

Journal of translational medicine, 2014-05, Vol.12 (1), p.116-116

2014

Volltextzugriff (PDF)

Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI - Mel.A.) [ISRCTN75125874]

BMC cancer, 2006-02, Vol.6 (1), p.44-44, Article 44

2006

Volltextzugriff (PDF)

Erratum to “Unexpected High Response Rate to Traditional Therapy after Dendritic Cell-Based Vaccine in Advanced Melanoma: Update of Clinical Outcome and Subgroup Analysis”

Clinical & developmental immunology, 2011, Vol.2011 (2011), p.1-1

2011

Volltextzugriff (PDF)

Epidemiological burden and causal factors of childhood cancer: too many uncertainties

Epidemiologia e prevenzione, 2018-03, Vol.42 (2), p.104

2018

Volltextzugriff (PDF)

Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy

Cancer Immunology, Immunotherapy, 2012-01, Vol.61 (1), p.41-48

2012

Volltextzugriff (PDF)

Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response

Journal of translational medicine, 2014-09, Vol.12 (1), p.262-262, Article 262

2014

Volltextzugriff (PDF)

Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients

Journal of translational medicine, 2013-05, Vol.11 (1), p.135-135

2013

Volltextzugriff (PDF)

Ipilimumab in advanced melanoma: reports of long-lasting responses

Melanoma research, 2012-06, Vol.22 (3), p.263-270

2012

Volltextzugriff (PDF)

The Italian Network for Tumor Biotherapy (NIBIT): getting together to push the field forward

Journal of translational medicine, 2008-02, Vol.6 (1), p.8-8, Article 8

2008

Volltextzugriff (PDF)

Defining the critical hurdles in cancer immunotherapy

Journal of translational medicine, 2011-12, Vol.9 (1), p.214-214, Article 214

2011

Volltextzugriff (PDF)

Dendritic cell vaccination for metastatic melanoma: a 14-year monoinstitutional experience

Melanoma research, 2017-08, Vol.27 (4), p.351-357

2017

Volltextzugriff (PDF)

SENTIERI studies: scientific evidence and lack of use for prevention

Epidemiologia e prevenzione, 2015-03, Vol.39 (2), p.134

2015

Volltextzugriff (PDF)

Anti-CTLA-4 therapy in melanoma: role of ipilimumab (MDX-010)

Expert review of dermatology, 2009-06, Vol.4 (3), p.199-210

2009

Volltextzugriff (PDF)

1 – 25 von 92

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(88)
Mit Volltextzugriff
(62)

Publikationsform

Artikel
(92)

Sprache

Englisch
(89)
Italienisch
(3)

Erscheinungsjahr

n.n

Thema

Humans
(60)
Life Sciences & Biomedicine
(60)
Science & Technology
(60)
Oncology
(43)
Female
(37)
Male
(36)
Middle Aged
(35)
Aged
(33)
Adult
(30)
Melanoma
(24)
Medicine, Research & Experimental
(19)
Research & Experimental Medicine
(19)
Treatment Outcome
(19)
Immunotherapy
(18)
Dermatology
(16)
Italy
(16)
Melanoma - Drug Therapy
(16)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(14)
Biological And Medical Sciences
(14)
Immunology
(14)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma

Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial

Evaluation of in vivo labelled dendritic cell migration in cancer patients

The cost of unresectable stage III or stage IV melanoma in Italy

Cisplatin, Dacarbazine With or Without Subcutaneous Interleukin-2, and Interferon Alfa-2b in Advanced Melanoma Outpatients: Results From an Italian Multicenter Phase III Randomized Clinical Trial

Adding Gemcitabine to Paclitaxel/Carboplatin Combination Increases Survival in Advanced Non–Small-Cell Lung Cancer: Results of a Phase II-III Study

Improved overall survival in dendritic cell vaccination-induced immunoreactive subgroup of advanced melanoma patients

Unexpected High Response Rate to Traditional Therapy after Dendritic Cell-Based Vaccine in Advanced Melanoma: Update of Clinical Outcome and Subgroup Analysis

FRET microscopy autologous tumor lysate processing in mature dendritic cell vaccine therapy

Biomonitoring of Metals in Children Living in an Urban Area and Close to Waste Incinerators

Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort

Tolerability of intensified intravenous interferon alfa-2b versus the ECOG 1684 schedule as adjuvant therapy for stage III melanoma: a randomized phase III Italian Melanoma Inter-group trial (IMI - Mel.A.) [ISRCTN75125874]

Erratum to “Unexpected High Response Rate to Traditional Therapy after Dendritic Cell-Based Vaccine in Advanced Melanoma: Update of Clinical Outcome and Subgroup Analysis”

Epidemiological burden and causal factors of childhood cancer: too many uncertainties

Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy

Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program

Radiotherapy as an immunological booster in patients with metastatic melanoma or renal cell carcinoma treated with high-dose Interleukin-2: evaluation of biomarkers of immunologic and therapeutic response

Low-dose temozolomide before dendritic-cell vaccination reduces (specifically) CD4+CD25++Foxp3+ regulatory T-cells in advanced melanoma patients

Ipilimumab in advanced melanoma: reports of long-lasting responses

The Italian Network for Tumor Biotherapy (NIBIT): getting together to push the field forward

Defining the critical hurdles in cancer immunotherapy

Dendritic cell vaccination for metastatic melanoma: a 14-year monoinstitutional experience

SENTIERI studies: scientific evidence and lack of use for prevention

Anti-CTLA-4 therapy in melanoma: role of ipilimumab (MDX-010)

Gemcitabine, oxaliplatin, levofolinate, 5-fluorouracil, granulocyte-macrophage colony-stimulating factor, and interleukin-2 (GOLFIG) versus FOLFOX chemotherapy in metastatic colorectal cancer patients: the GOLFIG-2 multicentric open-label randomized phase III trial

Suchergebnisse filtern